Legend Biotech, the US-listed biopharmaceutical company with significant operations in the UK and Europe, announced today that chief executive Ying Huang has stepped down. Alan Bash, who served as chief operating officer, has been named interim CEO with immediate effect as the board begins a search for a permanent successor.
The leadership transition comes at a critical time for the company. Legend Biotech is best known for its CAR-T cell therapy, Carvykti (ciltacabtagene autoleucel), which is approved for the treatment of multiple myeloma. The therapy is co-developed and commercialised in partnership with Johnson & Johnson, and has been a key driver of the company's valuation on the Nasdaq.
Analysts noted that the sudden departure of Huang, who had led the company since its early stages, may introduce short-term uncertainty. However, Bash's deep operational knowledge of the Carvykti programme and manufacturing scale-up is seen as a stabilising factor. The company has been working to expand production capacity in Europe, including at its facility in Belgium, to meet growing demand.
For UK investors, the news is a reminder of the volatility inherent in the biotech sector. Legend Biotech does not have a direct listing on the London Stock Exchange, but its performance influences sentiment around UK-listed biotech peers and the broader healthcare investment landscape. Pension funds with exposure to US healthcare equities may see some near-term fluctuation in their portfolios.
The board has stated it will conduct a thorough search for a permanent CEO, considering both internal and external candidates. In the interim, Bash is expected to maintain the company's strategic focus on regulatory approvals and commercial expansion in the UK and European markets.